Aardvark therapeutics announces ard-201 preclinical obesity data showing significant weight loss as a monotherapy, enhancement of glp-1ra therapy in combination, and effective maintenance following discontinuation of glp-1ra therapy

In a gold-standard model of obesity, treatment with ard-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ard-201 was also associated with attenuated weight regain after discontinuation of tirzepatide.
AARD Ratings Summary
AARD Quant Ranking